JPMorgan Chase & Co. Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $64.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price cut by JPMorgan Chase & Co. from $72.00 to $64.00 in a research report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. A number of other equities research analysts have also weighed in on APLS. HC Wainwright cut […]
More Stories
Musk’s xAI Plans $20 Billion Mississippi Data Center in Largest Investment in State History
By Evgenia Filimianova Elon Musk’s artificial intelligence startup xAI plans to invest more than $20 billion to build a large...
3,200 Percent Increase in Vehicular Attacks Against ICE Officers: DHS
By Naveen Athrappully U.S. Immigration and Customs Enforcement personnel have faced more than a 1,300 percent increase in assaults and...
Rio Tinto in Talks to Buy Glencore in Potential Mega-Merger
By Evgenia Filimianova Rio Tinto is in early discussions to buy rival Glencore, the two companies said this week, a...
Trump Says US Will Begin Land Strikes on Cartels in Mexico
By Joseph Lord and Kimberly Hayek President Donald Trump announced in an interview aired Jan. 8 that the United States...
Argentina Repays $20 Billion US Swap Line, Bessent Says
By Andrew Moran Treasury Secretary Scott Bessent said on Jan. 9 that Argentina has repaid a drawdown on the $20...
US Economy Posts Modest Job Gains in December
By Andrew Moran U.S. payrolls climbed less than expected in December, while the unemployment rate came in below market estimates,...